Talicia FDA Approval History
Last updated by Judith Stewart, BPharm on June 22, 2020.
FDA Approved: Yes (First approved November 4, 2019)
Brand name: Talicia
Generic name: amoxicillin, omeprazole and rifabutin
Dosage form: Delayed-Release Capsules
Company: RedHill Biopharma Ltd.
Treatment for: Helicobacter Pylori Infection
Talicia (omeprazole magnesium, amoxicillin and rifabutin) is a fixed-dose combination of two antibiotics, (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole) for the treatment of Helicobacter pylori (H. pylori) infection.
- H. pylori is classified as a Group I carcinogen and is considered a significant risk factor for the development of gastric cancer. H. pylori infection affects approximately 35% of the U.S. population and is also a major cause of peptic ulcer and gastritis.
- Treatment of H. pylori infection has become increasingly difficult over the past decade due to bacterial resistance and diminished efficacy of clarithromycin-based standard-of-care therapies. Talicia is the first and only FDA approved rifabutin-based H. pylori therapy. It is designed to address the problem of growing H. pylori resistance to clarithromycin.
- FDA approval of Talicia approval is based, in part, on the results of two positive Phase 3 studies in H. pylori-positive adult patients complaining of epigastric pain and/or discomfort. The ERADICATE Hp2 confirmatory Phase 3 study of Talicia demonstrated 84% eradication of H. pylori infection with Talicia versus 58% in the active comparator (amoxicillin and omeprazole) arm (p<0.0001).
- Common adverse reactions include diarrhea, headache, nausea, abdominal pain, chromaturia (abnormal coloration of the urine), rash, dyspepsia, oropharyngeal pain (sore throat), vomiting, and vulvovaginal candidiasis (yeast infection).
Development Timeline for Talicia
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.